Filing Details

Accession Number:
0001735276-21-000041
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-21 18:22:42
Reporting Period:
2021-04-19
Accepted Time:
2021-04-21 18:22:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1458494 Akshay Vaishnaw 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
President, R&d No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-19 5,083 $0.00 22,908 No 4 A Direct
Common Stock Disposition 2021-04-19 1,678 $136.76 21,230 No 4 S Direct
Common Stock Disposition 2021-04-19 989 $137.60 20,241 No 4 S Direct
Common Stock Disposition 2021-04-19 622 $138.64 19,619 No 4 S Direct
Common Stock Disposition 2021-04-19 417 $140.02 19,202 No 4 S Direct
Common Stock Disposition 2021-04-20 2,266 $131.75 16,936 No 4 F Direct
Common Stock Disposition 2021-04-20 85 $134.56 16,851 No 4 F Direct
Common Stock Disposition 2021-04-21 203 $135.41 16,648 No 4 S Direct
Common Stock Disposition 2021-04-21 1,892 $136.84 14,756 No 4 S Direct
Common Stock Disposition 2021-04-21 530 $137.60 14,226 No 4 S Direct
Common Stock Disposition 2021-04-21 107 $138.48 14,119 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 F Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 515 Indirect by Managed Account
Footnotes
  1. On February 26, 2020, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and one-third of the PSU award vested as of April 19, 2021.
  2. All sales reported on this Form 4, other than the sell-to-cover for taxes on April 20, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021.
  3. Sale prices ranged from $136.21 to $137.17.
  4. Sale prices ranged from $137.28 to $138.13.
  5. Sale prices ranged from $138.34 to $139.27.
  6. Sale prices ranged from $139.72 to $140.18.
  7. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
  8. Sale prices ranged from $135.24 to $135.96.
  9. Sale prices ranged from $136.41 to $137.33.
  10. Sale prices ranged from $137.42 to $138.10.
  11. Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.